Moderna launches COVID booster campaignHollan, MikePatient Care (Online)
A new report accuses American drugmaker Moderna of prioritizing profits from COVID-19 vaccines by keeping poor countries waiting. The New York Times says the vaccine maker has sold most of its doses to wealthier nations. Only one million doses have gone to low-income countries...
During anAxios COVID-19 vaccine eventon May 19, both the CEO of Moderna and the CEO of Pfizer said that depending on the research being done on the efficacy and longevity of the vaccines, a booster shot could be needed between either eight to 12 months after the recipient’s initial...
Moderna aims to roll out a combined COVID-flu-RSV booster vaccine in late 2023, the US pharmaceutical firm said Monday, hoping a joint jab would encourage people to get an annual shot. The single vaccine for COVID-19, influenza andrespiratory syncytial virus—a common virus that causes the ...
Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial. mRNA-1273.214 stimulated almost twice the neutralising antibody lev
CAMBRIDGE (CBS) -- The FDA on Fridayauthorized Moderna and Pfizer's COVID vaccine booster shotsfor all adults 18 and older. A few hours later, CDC vaccine advisers voted unanimously to recommend allowing the booster shots for all, and CDC Director Rochelle Walensky endorsed the advisory committe...
The art of COVID-19 communication Call for global biodiversity agreementModerna said it is looking at whether a booster shot – either of its existing vaccine or of a new shot designed to protect against the South Africa variant – could be made available in future if evidence...
The Centers for Disease Control and Prevention formally recommended booster shots for many recipients of Moderna and Johnson & Johnson'sCOVID-19 vaccineson Thursday. As a result, up to 99 million Americans are now eligible for additional doses. ...
The old vaccines, which were designed to fight the original Covid strain, are no longer providing meaningful protection against infection and mild illness because the virus has mutated so much. There is also concern that the original shots' effectiveness at preve...
" said Stéphane Bancel, Chief Executive Officer of Moderna. "Our latest bivalent booster candidate, mRNA-1273.214, which combines the currently authorized Moderna COVID-19 booster with our Omicron-specific booster candidate, remains our lead candidate for the fall 2022 Northern...